Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $104

Wedbush analyst Andreas Argyrides maintains $MoonLake Immunotherapeutics(MLTX.US)$ with a buy rating, and adjusts the target price from $92 to $104.According to TipRanks data, the analyst has a succes

Futu NewsJun 25 20:31 · Ratings

Express News | MoonLake Immunotherapeutics : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $104

BreakingsJun 25 20:24

MoonLake Immunotherap Initiated at Outperform by Oppenheimer

Dow JonesJun 25 17:58

MoonLake Immunotherap Price Target Announced at $104.00/Share by Oppenheimer

Dow JonesJun 25 17:58

Oppenheimer Initiates Coverage On MoonLake With Outperform Rating, Announces Price Target of $104

Analyst UpgradesJun 25 17:48

Psoriasis Market to Register Incremental Growth by 2034, Predicts DelveInsight | Key Companies - AnaptysBio, Nimbus Lakshmi, Takeda, MoonLake Immunotherapeutics, Bristol-Myers Squibb, Amgen, Dermavant Sciences

PR NewswireJun 25 05:31